Completed PHASE1 INTERVENTIONAL 3-arm NCT06179537

Evaluation of the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects

A Phase I, Double-Blind, Randomised, Adaptive-designed Study to Assess the Pharmacokinetics and Safety of BLU-5937 in Healthy Adult Japanese and Caucasian Subjects Following Single and Multiple Oral Doses

Sponsor: Bellus Health Inc. - a GSK company

Conditions Healthy

Interventions BLU-5937

Updated 3 times since 2024 Last updated: Dec 19, 2023 Started: Aug 6, 2021 Primary completion: Oct 22, 2021 Completion: Nov 21, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06179537, this PHASE1 trial focuses on Healthy and remains completed. Sponsored by Bellus Health Inc. - a GSK company, it has been updated 3 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2024 — Jul 2024 [monthly]

Completed PHASE1

First recorded

Aug 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Bellus Health Inc. - a GSK company

Data source: Bellus Health Inc. - a GSK company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom